Literature DB >> 33606910

Use of a clinical trial screening tool to enhance patient accrual.

Diane C St Germain1, Worta McCaskill-Stevens1.   

Abstract

BACKGROUND: Clinical trial patient accrual continues to be challenging despite the identification of multiple physician, patient, and system barriers. Expanded collection of demographic data, including socioeconomic status (employment, income, education) and comorbidities, can enhance our understanding of the identified barriers, inform the development of interventions to overcome these barriers, and recognize their impact on treatment outcomes. A clinical trials screening tool was developed to collect expanded demographic data and barriers to trial enrollment; it has been implemented in the National Cancer Institute Clinical Oncology Research Program. The purpose of this article is to describe the development and implementation of the tool and to share information obtained during the first 43 months of its use.
METHODS: There were 19,373 entries collected; 74% of those screened enrolled in a clinical trial. Demographic characteristics were compared between those screened and those enrolled. They varied significantly between the groups.
RESULTS: Reasons for nonenrollment included ineligibility (50%), eligible but declined (47%), eligible but physician declined to offer participation (2%), and eligible but the study was suspended (1%). The most common reasons for ineligibility were failure to meet the protocol-specific stage of cancer, the presence of comorbidities, and the symptom-eligibility score was not met. The most common reason for eligible patients declining participation was that they had no desire to participate in research.
CONCLUSIONS: The tool provides valuable information about the characteristics of individuals who are screened and enrolled in National Cancer Institute-sponsored trials, as well as about barriers to enrollment in trials. The data also inform protocol development and interventions at the patient, provider, and institutional level.
© 2021 American Cancer Society.

Entities:  

Keywords:  National Cancer Institute; data collection; physician-patient relations

Mesh:

Year:  2021        PMID: 33606910     DOI: 10.1002/cncr.33399

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study.

Authors:  Sonia Pernas; Patricia Villagrasa; Ana Vivancos; Maurizio Scaltriti; Jordi Rodón; Octavio Burgués; Paolo Nuciforo; Jordi Canes; Laia Paré; Marta Dueñas; Maria Vidal; Juan Miguel Cejalvo; Antonia Perelló; Antonio Llommbard-Cussac; Joan Dorca; Alvaro Montaño; Tomás Pascual; Mafalda Oliveira; Gloria Ribas; Inmaculada Rapado; Aleix Prat; Eva Ciruelos
Journal:  Front Oncol       Date:  2021-11-04       Impact factor: 6.244

2.  Strategies to improve diversity, equity, and inclusion in clinical trials.

Authors:  Justine M Kahn; Darrell M Gray; Jill M Oliveri; Chasity M Washington; Cecilia R DeGraffinreid; Electra D Paskett
Journal:  Cancer       Date:  2021-09-08       Impact factor: 6.921

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.